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mutation. There was no gender difference in ER expression. The 
survival time for patients with the ER mutation was longer (median 
survival time 44.5 months versus 23.5 months), however these differ-
ences were not statistically signiﬁcant. 
Conclusions: There were strong correlation between ERβ and ERCC1 
expression. These expressions may play a role simultaneously in the 
development of adenocarcinoma of the lung.
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Introduction: Epigenetic alterations in certain genes are now known 
as at least important as genetic mutation in pathogenesis of cancer. 
Especially abnormal promotor region methylation in tumor suppressor 
genes is known to result in gene silencing and therefore loss of gene 
function. Objective We, the authors, wanted to search for new lung 
cancer-speciﬁc tumor suppressor genes through the study, and to ﬁgure 
out the roll of known tumor suppressor genes of other kinds of cancer 
for NSCLC as well. 
Material and Methods: Cancer tissue & adjacent normal tissue were 
obtained from 10 patients who diagnosed with NSCLC and underwent 
surgery in Konyang university hospital in 2005. NotI-MseI Methyla-
tion chip was used to analyze DNA methylation on promoter region of 
27 genes in tumor tissue & nearby normally-appearing tissue. The rate 
of methylation was measured and compared for both groups to ﬁnd 
out the genes associated with tomorigenesis. Also the patients were 
grouped by age, gender, history of smoking, and cell type of NSCLC, 
and compared between groups. And as normal control group we ob-
tained lung tissue from two young patients with pneumothorax during 
their bullectomies, methylations were examinated in the same way and 
compared with tumor and non-tumor tissue from NSCLC patients. 
Result: Among the 27 genes, the higher rate of methylation for tumor 
tissue than that of non-tumor tissue were observed in 14 genes, and 6 
genes including AR, HTR1B, CFTR from those 14 genes in normal 
lung tissue were not methylated, suggesting the possibility of the role 
for TSG(tumor suppressor gene) of NSCLC.
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Immunohistochemical study for the expression of DR5 TRAIL 
receptor in non-small cell lung cancer
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Background: KILLER/DR5 is a recently identiﬁed p53-regulated 
death recpetor gene that was induced by doxorubicine only in cells with 
wild-type p53 status. KILLER gene was also independently identiﬁed 
as a TRAIL (TNF-related Apoptosis-inducing Ligand) death receptor, 
DR5. KILLER/DR5 is now considered as one of the p53-dependent 
apoptotic genes such as fas, bax, or insulin-like growth factor-binding 
protein 3. However, examination of KILLER/DR5 in primary tumour 
tissue has not yet been reported. In this study, we demonstrate that 
KILLER/DR5 expression is dependent on wild-type p53 status in non-
small cell lung cancer (NSCLC). 
Methods and Materials: Immunohistochemical analysis using the 
avidin-biotinylated horseradish peroxidase complex was carried out in 
eighty-nine surgically resected NSCLC formalin-ﬁxed parafﬁn-embed-
ded tissue sections. As primary antibodies, we used anti-DR5 poly-
clonal antibody (Pro Sci Inc., Poway, CA) and anti-p53 monoclonal 
antibody (DO-7, Novocastra, Inc, Manhasset, NY). A negative control 
was processed with each slide; it excluded the primary antibody but in-
cluded all other steps of the procedure. Positive tumor cells were quan-
tiﬁed twice, expressed as a percentage of the total number of tumor 
cells, and the intensity of immunostaining: 1+, weak and diffuse(>50%) 
or focal (<50%) or moderate and focal; 2+, strong and focal or moder-
ate and diffuse; 3+, strong and diffuse. The analysis of DR5 expression 
was done separately in tumor area and regional normal area. 
Results: DR5 expression was high ( > 2+) in bronchial epithelium 
(89% of cases) but almost absent in type I & II pneumocytes, lympho-
cytes, and smooth muscle cells. High DR5 expression rate in tumor was 
28% (15/53) in squamous cell carcinoma, 47%(15/32) in adenocarci-
noma, and 50% (2/4) in large cell carcinoma, overall 36%. DR5 expres-
sion did not show any statistical signiﬁcance with T stage, N stage, 
and survival. However, DR5 expressiont showed signiﬁcant inverse 
correlation with p53 expression. (p < 0.01). If p53 expression was high, 
there was no expression in DR5 and vice versa. 
Conclusions: This signiﬁcant in vivo correlation between p53 expres-
sion and KILLER/DR5 expression is highly suggestive for the fact that 
KILLER/DR5 is one of important p53-dependent apoptotic genes.
P3-010 BSTB: Molecular Pathology Posters, Wed, Sept 5 – Thur, Sept 6 
Using immunohistochemistry to evaluate protein expression levels 
of female sex hormone receptors (ER, PR) and epidermal growth 
factor receptor family members (EGFR, HER2) in East Asian non-
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Background: The non-smoking East Asian female with lung adenocar-
cinoma is a phenotype that has been correlated with higher frequencies 
of EGFR mutations, with corresponding increased tumor response to 
tyrosine kinase inhibitors. We hypothesize that estrogen receptor (ER) 
has a role in the biological mechanism underlying this clinical entity, in 
a combinatorial fashion with other signaling transduction components. 
Here, we examine the protein expression levels via immunohistochem-
istry of isoforms of ER, namely ERα and ERβ, progesterone receptor 
(PR), EGFR and HER2.
Methods: Tissue microarrays (TMA): These were constructed from 
parafﬁn-embedded blocks of surgically resected tissues. Each array was 
targeted to contain replicates of 33 adenocarcinomas and 16 squamous 
cell carcinomas, of which 26 and 2 had matched normal lung tissues, 
respectively. 
Immunohistochemistry: Commercially available antibodies identify-
ing ERα, ERβ, PR, EGFR and HER2 were used for staining and detec-
tion, according to the manufacturers’ protocols. The ER, PR and HER2 
analyses used breast invasive ductal carcinomas as positive controls. 
Extent (% of cells) and intensity of staining were scored on a scale of 
